Prognostic Value of Neutrophil-Related Factors in Locally Advanced Cervical Squamous Cell Carcinoma Patients Treated with Cisplatin-Based Concurrent Chemoradiotherapy
Table 2
Univariate survival analysis of PFS and OS in patients with LACSCC.
Clinicopathologic characteristics
PFS
value
OS
value
Mean ± SD (months)
95% CI
Mean ± SD (months)
95% CI
Age
≤50 years
40.24 ± 4.51
−1.775–19.821
0.100
45.36 ± 4.01
−4.218–15.562
0.255
>50 years
49.26 ± 3.23
51.03 ± 3.04
Histologic grade
Well and moderately differentiated
47.72 ± 3.27
−16.953–5.247
0.295
49.71 ± 3.69
−11.964–8.132
0.704
Poorly differentiated
41.87 ± 4.68
47.79 ± 3.31
Tumor size
≤4 cm
44.84 ± 3.60
−13.095–9.726
0.769
48.79 ± 3.17
−9.832–11.016
0.910
>4 cm
46.52 ± 4.02
48.20 ± 3.87
Parametrial invasion
No
43.68 ± 3.01
−22.467–7.181
0.877
46.18 ± 2.43
−21.708–4.791
0.295
Unilateral
51.32 ± 4.13
54.63 ± 3.15
Bilateral
40.25 ± 2.58
44.27 ± 4.21
Clinical lymph node involvement
cN0
48.80 ± 2.87
1.140–25.259
0.032
51.72 ± 2.55
1.283–22.960
0.029
cN1
35.60 ± 5.96
39.60 ± 5.55
FIGO stage
II
45.78 ± 3.51
−10.341–12.072
0.878
52.57 ± 2.77
0.286–19.813
0.044
III
44.91 ± 4.32
42.52 ± 4.28
Hemoglobin levels at diagnosis (g/dL)
≤113
44.14 ± 6.41
−11.144–14.545
0.792
47.08 ± 6.16
−9.923–13.816
0.743
>113
45.84 ± 2.97
49.02 ± 2.64
Platelets at diagnosis (g/dL)
≤320
36.50 ± 8.30
−25.057–3.521
0.136
42.60 ± 7.69
−20.208–5.738
0.269
>320
47.27 ± 2.75
49.83 ± 2.49
Response
CR
48.09 ± 3.47
−4.490–17.499
0.241
52.11 ± 2.89
−0.9463–18.740
0.075
Non-CR
41.58 ± 4.26
43.22 ± 4.15
NLR
≥2.0
46.94 ± 3.49
−9.711–14.331
0.701
43.06 ± 3.61
−21.842–0.356
0.043
<2.0
44.63 ± 4.96
54.16 ± 3.15
PFS, progression-free survival; OS, overall survival; LACSCC, locally advanced cervical squamous cell carcinomas; FIGO, International Federation of Gynecology and Obstetrics; CR, complete response; NLR, neutrophil-lymphocyte ratio.
